Description: Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Home Page: acumenpharm.com
ABOS Technical Analysis
427 Park Street
Charlottesville,
VA
22902
United States
Phone:
434 297 1000
Officers
| Name | Title |
|---|---|
| Mr. Daniel J. O'Connell M.B.A. | CEO, Pres & Director |
| Mr. Matt Zuga | CFO, Chief Bus. Officer & Corp. Sec. |
| Dr. Eric Siemers M.D. | Chief Medical Officer |
| Mr. Russell Barton M.S. | Chief Operating Officer |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer |
| Ms. Robyn Moxon M.A. | Mang. of Corp. & Clinical Communications |
| Ms. Julie Bockenstette | Exec. VP & Head of HR |
| Ms. Siew Tin Gan M.S. | Assistant VP & Head of Clinical Operations |
| Ms. Janice Hitchcock | VP & Head of Regulatory Affairs |
| Ms. Liean Schenck M.S. | VP & Head of CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 4.0074 |
| Price-to-Book MRQ: | 1.1987 |
| Price-to-Sales TTM: | 538.7842 |
| IPO Date: | 2021-07-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |